Working like the multiple-flash, red-eye reduction function in a digital camera, SenoBright uses X-rays at multiple energies to create two separate exposures. These resulting images specifically illuminate and highlight areas where there is angiogenesis, growth of small blood vessels potentially related to the presence of cancer.
"A CESM exam takes from 5 to 10 minutes", stated Dr. Clarisse Dromain, Gustave Roussy Cancer Institute, France. "During my investigation of the use of CESM with my own examinations of patients, I have been able to better define the spread of a cancer compared to standard mammography and ultrasound, and follow-up exams with an MRI (Magnetic Resonance Imaging) validated exactly the same results. Moreover, in the majority of cases the confidence in the diagnosis is high enough that the patient can be told the results that same day", she added.
SenoBright enables the digital mammography system to detect a whole new type of diagnostic information. Standard mammography only sees the structure of breast tissue. With SenoBright, doctors can also locate the proliferation of small blood vessels, potentially associated with cancerous tumour growth. In addition, it shows potential for measuring the extension of the lesion to help to plan surgery and treatment. Patients receive an intravenous injection of standard iodine contrast agent, and after two minutes undergo a five-minute digital mammography exam. CESM images are acquired in familiar mammography views so that that they can be quickly and easily correlated with standard results, facilitating interpretation by other specialists like surgeons or oncologists.
"Worldwide, more than 1,2 million people annually are diagnosed with breast cancer. Since 1965, GE Healthcare has made significant progress in providing solutions for breast cancer detection and diagnosis that really bring a change to people's lives. Today through "healthymagination", we continuously develop innovations to reduce costs, increase access and improve quality and efficiency of health care delivery around the globe", stated Reinaldo Garcia, President and CEO of GE Healthcare for Europe, Middle East and Africa (EMEA). "GE Healthcare is pleased to bring to market such advanced breast imaging technologies like SenoBright, the result of over 10 years and $12 million investment of research and clinical collaborations. This innovative technology will support the earlier diagnosis of this prevalent disease, by providing access to new diagnostic information at a lower cost."
The product development was carried out in collaboration between GE Healthcare and Qatar Science & Technology Park (QSTP). The goal of the joint research programme is to develop new and innovative technologies for aiding in the diagnosis of breast cancer using the latest developments in digital mammography.
Dr. Tidu Maini, Science and Technology Advisor to Her Highness, Sheikha Mozah bint Nasser Al Missned, and Executive Chairman of Qatar Science & Technology Park, stated: "Our collaboration with GE Healthcare is a step towards making Qatar a global medical innovator while delivering real health benefits for the local community."
SenoBright is an easy procedure that can be conducted by the same staff, using the same mammography equipment, potentially on the same day as the exam - allowing medical professionals to cut the critical time patients often have to wait from detection to diagnosis.
"Given our proven history of breast imaging innovations, GE is proud to release yet another innovative technology, soon to be available to much of our digital installed base. We are one of the only companies today to engineer and manufacture the entire mammography imaging chain from tube, and detector to review workstation, coupled with integration of the comprehensive local requirements for each customer", stated David Caumartin, GE Healthcare's General Manager Mammography. "SenoBright is likely to be a key enabler of accelerated patient work flow from diagnostics to treatment planning. It is enhancing the widely accepted technology of digital mammography by adding the functional information in order to detect angiogenesis."
Digital mammography is considered a relevant means of breast cancer screening, delivering proven clinical outcomes. The sensitivity and specificity of images can, however, be affected by a range of factors. Dense breast tissue can overlap with lesions, which are not always visible on an X-ray, and radiologists' interpretation of images can vary.
Inconclusive digital mammography presents a range of challenges to health care professionals and patients. Ambiguity can result in diagnostic error, demanding further tests that can include ultrasound, invasive biopsy and Magnetic Resonance Imaging (MRI) scanning - all of which could delay the diagnostic process, in some cases by weeks or even months.
SenoBright can remove this ambiguity, helping to ensure that those patients who need to go into cancer treatment do so - and do so quickly. Whereas patients who do not have malignant lesions have the potential to find out on the same day, relieving their burden of uncertainty. Compared to mammography alone, clinical studies show that SenoBright improves sensitivity and specificity:
- for every 100 cancers, there is the potential to find 13 more
- 6 more benign lesions out of 100 can be correctly classified
- 19 more patients out of 100 without cancer can be sent home